Clinical trial NCT04893980: Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria
Official title: Short-term Efficacy of Low-dose Interleukin-2 Treatment in Chrornic Spontaneous Urticaria: a Randomized, Controlled, Single-center Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Chronic Spontaneous Urticaria
Keywords: chronic urticaria
interleukin-2
Lead sponsor: Second Xiangya Hospital of Central South University
Sponsor class: OTHER
First posted: 2021-05-20
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a randomized, controlled, single-center clinical study to evaluate the short-term efficacy of low-dose Interleukin-2 injection as an add-on therapy for the treatment of patients aged 18-75 who have been diagnosed with CSU and remain symptomatic despite oral antihistamine treatment .

Detailed description: Backgrounds:

Urticaria is a common disorder that present with localized edema reaction caused by dilatation and increased permeability of small blood vessels in skin and mucosa. The main clinical manifestations are wheal and erythema reaction.

Chronic spontaneous urticaria (CSU) is defined as the recurrent, transient (\<24h), pruritic wheals of the skin and mucosa lasting for more than 6 weeks ,with or without angioedema, excluding chronic inducible urticaria and urticarial vasculitis. Among all patients with chronic urticaria, CSU patients accounts for about 80%. Although the pathogenesis of CSU is still unclear, increasing evidence has shown an autoimmune feature of this chronic disease. Oral antihistamines are the mainstay of treatment for patients with CSU. However, a proportion of patients with CSU remain symptomatic despite treatment with standard- or doubled-dose of antihistamines. In recent years, studies have shown that low-dose recombinant human IL-2 (rhIL-2) treatment has good therapeutic effect in a variety of autoimmune diseases, such as systemic lupus erythematosus, type 1 diabetes, without serious side reactions. Therefore, we propose low-dose rhIL-2 as an add-on treatment for patient with CSU that are recalcitrant to treatment with antihistamines. Here we designed this clinical trial to explore its therapeutic effect as well as therapeutic mechanisms.

Design of Study:

This is a randomized, controlled, single-center clinical trial to assess the short-term efficacy of rhIL-2 treatment for patients with CSU.

Methods:

RhIL-2 injection combined with the current dose of antihistamine (Use one kind or two to three kinds in combination, and use one or two doses of each kind of antihistamine，keeping doses before enrollment) will be applied to CSU patients meeting the inclusion criteria. The end points include clinical response and immunological changes, as well as safety.

Eligibility criteria: Inclusion Criteria:

1. Age: between 18- and 75-years old;
2. Patients definitely diagnosed with chronic spontaneous urticaria according to 'Guideline for diagnosis and treatment of urticaria in China (2018) '; or chronic spontaneous urticaria has been diagnosed in the past.
3. Patients taking antihistamines daily ( one kind or two to three kinds in combination, with a standard- or doubled-dose of each kind of antihistamines) for at least one week and remain symptomatic with a UAS7 score of not less than 16;
4. Written informed consent was obtained, and the patient volunteers to participate in the project and complete the project as required.

Exclusion Criteria:

1. Patients with severe diseases of heart, brain, lungs, liver, kidney or blood system; patients experienced organ transplantation;
2. Patients with any acute severe infection such as pyemia and cellulitis, active tuberculosis, or an infection history of human immunodeficiency virus (HIV);
3. Patients have a clear history of allergy to rhIL-2;
4. Patients receiving Interleukin-2 treatment in the last 3 months by subcutaneous or intramuscular injection；
5. Patients with drug abuse, alcohol abuse, or mental disorders that are unable to cooperate or adhere to treatment;
6. Pregnant women, lactating women or women who are willing to conceive within 3 months;
7. Patients receiving glucocorticoid treatment in the last 4 weeks; Patients receiving cyclosporin treatment in the last 90 days；Patients receiving tripterygium wilfordii polyglycoside treatment in the last 6 months；Patients receiving Omalizumab treatment in the last 1 year；Other drugs used previously should be identified whether they are in the washout period one by one, and patients who have taken drugs that may have an impact on the study should be excluded during the washout period or screened again for enrollment after the washout period；
8. Patients who have participated in other clinical trials within 3 months before the screening.

Primary outcomes:
measure: The change of Urticaria Activity Score of 7 Days（UAS7）from baseline (Day 0) to Day 14.
timeFrame: from baseline to Day 14
Secondary outcomes:
measure: The change of UAS7 from baseline (Day 0) to Day 28 and Day 56, respectively.
timeFrame: from baseline to Day 28 and Day 56, respectively
measure: The change of chronic urticaria quality of life questionnaire (CU-Q2oL) score after a 14-, 28- and 56-day treatment, respectively.
timeFrame: from baseline to 14, 28 and 56 days, respectively
measure: The change of urticaria control test (UCT) after a 14-, 28- and 56-day treatment, respectively.
timeFrame: from baseline to 14, 28 and 56 days, respectively
measure: For patients with angioedema, the change of Angioedema Activity Score of 7days（AAS7）after a 14-, 28- and 56-day treatment, respectively.
timeFrame: from baseline to 14, 28 and 56 days, respectively
measure: For patients with angioedema, the change of Angioedema quality of life questionnaire(AE-QoL) after a 28- and 56-day treatment, respectively.
timeFrame: from baseline to 28 and 56 days, respectively
measure: The change of sera autoantibodies titer after a 14- and 28-day treatment, respectively.
timeFrame: from baseline to 14 and 28 days, respectively
measure: The change of accumulative dose of antihistamines in the past 7 days on Day 28 and Day 56, respectively, compared to baseline.
timeFrame: from baseline to 28 and 56 days, respectively
measure: Percentage of patients with UAS7 less than 6 on Day 14 and Day 28, respectively.
timeFrame: from baseline to 28 and 56 days, respectively
measure: The drug adverse reactions throughout the entire study process.
timeFrame: through study completion, an average of 56 days
Other outcomes:
Locations:
city: Changsha
country: China
facility: The Second Xiangya Hospital of Central South University
state: Hunan
Study officials:
affiliation: The Second Xiangya Hospital, Central South University
name: Qianjin Lu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: